Tolerance and immunogenicity of ProCervix, a HPV-16 & 18 therapeutic vaccine, in HPV infected women

Trial Profile

Tolerance and immunogenicity of ProCervix, a HPV-16 & 18 therapeutic vaccine, in HPV infected women

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs GTL 001 (Primary)
  • Indications Cervical cancer; Cervical dysplasia; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors GENTICEL
  • Most Recent Events

    • 01 Jun 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 01 Jun 2016 Results published online in Clinical Cancer Research, according to a Genticel media release.
    • 01 Jun 2016 Results published in a Genticel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top